Pharmacological treatment of cognitive deficits in Alzheimer's disease

被引：16

作者：

Brodaty, H

Ames, D

Boundy, KL

Hecker, J

Snowdon, J

Storey, E

Yates, MW ^{[1
]}

机构：

[1] Prince Wales Hosp, Acad Dept Old Age Psychiat, Randwick, NSW 2031, Australia

[2] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia

[3] Univ Melbourne, Royal Melbourne Hosp, Dept Psychiat, Parkville, Vic 3052, Australia

[4] NW Adelaide Hlth Serv, Clin Cognit Res Unit, Adelaide, SA, Australia

[5] Repatriat Gen Hosp, Dept Rehabil & Geriatr Care, Adelaide, SA, Australia

[6] Univ Sydney, Rozelle Hosp, Dept Psychol Med, Sydney, NSW 2006, Australia

[7] Monash Univ, Dept Neurosci, Melbourne, Vic 3004, Australia

[8] Alfred Hosp, Melbourne, Vic, Australia

[9] Queen Elizabeth Ctr, Ballarat Hlth Serv, Grampians Reg Cognit Dementia & Memory Serv, Ballarat, Vic, Australia

来源：

MEDICAL JOURNAL OF AUSTRALIA | 2001年 / 175卷 / 06期

关键词：

D O I：

10.5694/j.1326-5377.2001.tb143593.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical trials and independent reviews support the use of cholinesterase inhibitors for treating the symptoms of patients with mild to moderate Alzheimer's disease (AD). Before initiating cholinesterase inhibitor therapy, patients should be thoroughly assessed, and the diagnosis confirmed, preferably by a specialist. Compliance with cholinesterase inhibitor therapy should be monitored and the response (in global, cognitive, functional and behavioural domains) reassessed after 2-3 months of treatment. Vitamin E may be protective against AD, and therapy with 1000 lU twice daily may be considered. There is insufficient evidence to support the use of other antioxidant agents, anti-inflammatory agents, monoamine oxidase B inhibitors, folate/homocysteine or antihypertensive drugs in patients with AD, or hormone replacement therapy in affected women.

引用

页码：324 / 329

页数：6

共 51 条

[41] Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [J].